Mabion S.A., a Polish biotechnology company, has signed a letter of intent with French firm Oddifact SAS for the joint development of MabionCD20. The...
Mabion has unveiled its updated development strategy aimed at strengthening the Company’s position as a flexible, technologically advanced CDMO, securing new service-model contracts, and...